Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Cancer

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

01-05-2024

Med (New York, N.Y.)

Melanoma neoantigen vaccines: Are we getting more personal now?

12-04-2024

Cancer discovery

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.

05-04-2024

The Lancet regional health. Europe

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.

01-04-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.

01-04-2024

Journal for immunotherapy of cancer

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

26-03-2024

Cancer journal (Sudbury, Mass.)

Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma.

25-03-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

06-03-2024

Nature reviews. Clinical oncology

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

01-03-2024

EClinicalMedicine

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

01-03-2024

Cancer discovery

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.

01-03-2024

Journal for immunotherapy of cancer

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.

29-02-2024

Nature communications

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

23-02-2024

ESMO open

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.

01-02-2024

Clinical nuclear medicine

The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

01-02-2024

Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024

Journal for immunotherapy of cancer

No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC.

31-01-2024

Pigment cell & melanoma research

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

01-01-2024

Immuno-oncology technology

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.

01-12-2023

The New England journal of medicine

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

09-11-2023

Nature medicine

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

01-11-2023

Cancer discovery

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

05-10-2023

European urology open science

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

01-09-2023

Journal of cancer survivorship : research and practice

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

22-08-2023

ESMO open

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.

01-08-2023

Breast (Edinburgh, Scotland)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

01-08-2023

Annals of surgical oncology

Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma.

01-08-2023

International journal of cancer

Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.

15-07-2023

Journal for immunotherapy of cancer

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

01-07-2023

International journal of cancer

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

15-06-2023

The oncologist

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis.

02-06-2023

Nature biotechnology

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023

European journal of cancer (Oxford, England : 1990)

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

01-06-2023

ESMO open

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.

01-06-2023

Cancer chemotherapy and pharmacology

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

01-06-2023

Journal of immunotherapy (Hagerstown, Md. : 1997)

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

01-06-2023

Cancers

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

26-05-2023

Chinese clinical oncology

The emerging role for CAR T cells in solid tumor oncology.

01-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

01-04-2023

Open forum infectious diseases

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies.

01-04-2023

Cell reports. Medicine

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.

21-03-2023

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma. Reply.

02-03-2023

Critical reviews in oncology/hematology

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.

01-03-2023

British journal of cancer

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

01-03-2023

Current opinion in oncology

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers.

01-03-2023

Cancer treatment reviews

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

01-02-2023

ESMO open

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment.

01-02-2023